InvivoGen Insight Newsletters

Insight Newsletter - Winter 2015/16

InvivoGen Insight Winter 2014/15

- Antibody Isotype Families

   - Knockout Reporter Cell Lines

   - Reporter Detection Reagents

   - Endotoxin-free Selective Antibiotics

- Review: Improving the efficacy of clinical antibodies

Monoclonal antibodies (mAbs) have shown considerable success as cancer therapeutics and the number of anticancer mAbs in clinical use or under investigation has dramatically increased in recents years. However, there remains much room for improvement. Therapeutic antibodies act mainly by directly targeting tumor cells or by targeting immune cells in the tumor microenvironment....

  Previous Issues

Download our previous Newsletters (Acrobat required)

  • Winter 2015/16 - Improving the efficacy of clinical antibodies
  • Winter 2014/15 - Inflammasome activation: a matter of caspases
  • Winter 2013/14 - Deciphering the STING Paradox
  • Fall 2013 - β-Glucans: bittersweet ligands of Dectin-1
  • Spring 2013 - Multi-TLR Agonists: Potential for Therapeutic Success
  • Fall 2012 - Cytosolic DNA Sensors (CDSs): a STING in the tail
  • Summer 2012 - Lucia™, a novel secreted luciferase
  • Winter 2011 - Mycoplasma Detection and Elimination
  • Summer 2011 - Antibody and Vaccine adjuvants
  • Fall 2010 - Cytosolic dsDNA Sensors (CDS)
  • Spring 2010 - Lentiviral Vector Production
  • November 2009 - NLRP3 Inflammasome
  • Sept/Oct 2008 - DAMPs & DAMP Receptors
  • June/July 2008 - Vaccine Adjuvants
  • January 2008 - Immunoglobulin A
  • October 2007 - TLR9 Ligands
  • May 2007 - Toll-Like Receptor 4
  • December 2006 - RNA Interference
  • September 2006 - TLR7 and TLR8
  • May 2006 - Fc Fusion: pFUSE-Fc
  • November 2005 - Mycoplasma
  • September 2005 - TLR Signaling and IRF Activation Pathways
  • June 2005 - TLR Ligands


  • Load more Issues
    Hide
    Disclaimer: Our products are provided for research purpose only. Commercial applications may require licensing from third parties.
    Note that the sequence of available ORFs provided by InvivoGen can differ from a given reference Genbank record due to genetic variations and/or alternative splicing. Customers should verify that the version of a gene sold by InvivoGen is suitable for the customer needs.
    Copyrights © 2011-2016 InvivoGen. All Rights Reserved. Reproduction of any materials from this site is strictly forbidden without permission for commercial use. Nonprofit use for non-commercial research and educational purposes is permitted, citation should include the URL "www.invivogen.com".